St Louis, Missouri
Cancer clinical trials in St Louis, MO
287 cancer studies are recruiting participants at sites in St Louis as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
St Louis at a glance
- 287 studies are recruiting at a site in St Louis.
- By phase: Phase 1 (55), Phase 1/2 (46), Phase 2 (58), Phase 2/3 (6), Phase 3 (74), Phase 4 (1), No phase (24), Observational (23). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (148), university, hospital or other (105), government (34).
- By research area: Breast Cancer (86), Lung Cancer (70), Lymphoma (55), Prostate Cancer (40), Pancreatic Cancer (24), Melanoma (12).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in St Louis
Basic details from each study's public record (the 30 most recently updated of 287). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- Washington University School of Medicine
- Registry record
- NCT05696626 · updated
WashU DIEP Flap Video and Patient Understanding Improvement
- No phase
- Ages 18 and older
- Female participants
- Sponsor
- Washington University School of Medicine
- Study site
- Washington University School of Medicine
- Registry record
- NCT06864754 · updated
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT03418961 · updated
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT06058377 · updated
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study site
- Washington University Medicine
- Registry record
- NCT06270706 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Lung cancer studies recruiting in St Louis
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington University School of Medicine ( Site 3279)
- Registry record
- NCT07513376 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT04267848 · updated
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Missouri Baptist Medical Center
- Registry record
- NCT04665739 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South
- Registry record
- NCT06096844 · updated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South
- Registry record
- NCT06498635 · updated
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- Washington University School of Medicine
- Registry record
- NCT07100080 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Prostate cancer studies recruiting in St Louis
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO
- Registry record
- NCT05011383 · updated
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT04423211 · updated
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062)
- Registry record
- NCT06136624 · updated
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT03866382 · updated
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Amgen
- Study site
- Washington University
- Registry record
- NCT04221542 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Melanoma studies recruiting in St Louis
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital South · Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County
- Registry record
- NCT05136196 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in St Louis, MO on ClinicalTrials.gov.
Lymphoma studies recruiting in St Louis
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Study sites
- Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
- Registry record
- NCT06724237 · updated
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Siteman Cancer Center at Christian Hospital
- Registry record
- NCT03739814 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT04269902 · updated
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Siteman Cancer Center-South County · Washington University School of Medicine
- Registry record
- NCT04301076 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cardinal Glennon Children's Medical Center · Mercy Hospital Saint Louis · Washington University School of Medicine
- Registry record
- NCT04546399 · updated
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mercy Hospital South
- Registry record
- NCT04840602 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cardinal Glennon Children's Medical Center · Mercy Hospital Saint Louis · Siteman Cancer Center at Christian Hospital
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Missouri Baptist Medical Center · Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County
- Registry record
- NCT06337318 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in St Louis, MO on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in St Louis
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- Washington University
- Registry record
- NCT07644559 · updated
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT04858334 · updated
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Washington University School of Medicine
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Ask about studies near St Louis
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections